John Libbey Eurotext

European Journal of Dermatology

MENU

Short-term effect and safety of a new generation of monoclonal antibodies targeting interleukin-23p19 for treatment of psoriasis: a systematic review and meta-analysis Volume 29, numéro 3, May-June 2019

Illustrations

  • Figure 1
  • Figure 2
  • Figure 3
  • Figure 4
  • Figure 5
  • Figure 6
  • Figure 7
  • Figure 8
  • Figure 9
  • Figure 10

Tableaux

Auteurs
Department of Pharmacy, Institute of Surgery Research, Daping Hospital, Army Medical University, Chongqing 400042, P. R. China
* Reprints

Psoriasis is a chronic immune-mediated skin disease affecting approximately 2-3% people worldwide [1-3] and seriously affects patients’ physical and psychological well-being; it is therefore listed as an important research topic in the field of dermatology. However, the aetiology of psoriasis is complicated and has remained elusive, and psoriasis is thought to originate from an interplay between genetic, environmental, infectious, and lifestyle factors [4, 5]. Psoriasis is characterized by excessive [...]